Audentes Therapeutics Inc (BOLD)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO, CA 94108

Audentes Therapeutics, Inc. operates as a biotechnology company. The Company focuses on the development and commercialization of gene therapy treatments for people with serious rare diseases. Audentes Therapeutics serves customers in the United States.

Data based on most recent fiscal year report
Market Cap994.859 Million Shares Outstanding35.48 Million Avg Volume330.044 Thousand
1-Yr BETA vs S&P TR1.611 Current Ratio7.74 Quick Ratio7.74
View SEC Filings from BOLD instead.
Q1 2019 All Institutions Hedge Funds 1
To trade BOLD now:
Filers who had this stock in their top 10: 8 4 (0.41%)
13F Filers holding this stock: 137 31 (3.16%)
Aggregate 13F shares on 03/31/2019: 42.097 Million 13.427 Million
Aggregate 13F shares on 12/31/2018: 43.114 Million 13.22 Million
Percent change: -2.36% 1.57%
Funds creating new positions: 25 7
Funds Adding to an existing position: 48 10
Funds closing out their position: 14 3
Funds reducing their position: 41 9
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

 

Audentes Therapeutics Inc Chart by YCharts

Yahoo! Finance

finviz

Check out our reporting and analysis

Funds Holding BOLD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

31.6 Thousand total shares from 6 transactions

Exercise Derivative Conversion (M)

10 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MORRISON SCOTT W

  • Director
 0 2019-05-22 2

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

  • 10% Owner
 1,605,713 2019-05-21 0

GOLDBERG MARK ALAN

  • Director
 0 2019-05-17 2

PARMAR KUSH

  • Director
  • 10% Owner
 5,535,919 2019-05-16 1

PRASAD SUYASH SENIOR VP & CHIEF MED OFFICER

  • Officer
 18,236 2019-05-13 6

SILVERSTEIN JONATHAN

  • Director
 0 2019-05-08 0

HOLLES NATALIE C.

  • Director
 0 2019-03-29 3

5AM VENTURES III, L.P.

5AM CO-INVESTORS III, L.P.

5AM PARTNERS III, LLC

ROCKLAGE SCOTT M

DIEKMAN JOHN D

SCHWAB ANDREW J.

  • 10% Owner
 4,628,423 2019-03-28 0

MELTZ MARK A SVP, GENERAL COUNSEL

  • Officer
 0 2019-03-28 2

LANGE LOUIS G

  • Director
 358,375 2019-03-25 7

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD MGMT III, L.P.

DEERFIELD PRIVATE DESIGN FUND III, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
 498,219 2019-03-11 0

PATTERSON MATTHEW R CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 290,514 2019-02-25 7

SOLOWAY THOMAS P EXECUTIVE VICE PRESIDENT, CFO

  • Officer
 23,333 2019-02-06 1

SCHUETZ THOMAS J.

  • Director
 0 2019-02-06 2

SMITH JULIE

  • Director
 0 2019-02-06 2

JARRETT JENNIFER

  • Director
 0 2019-02-06 2

VERSANT VENTURE CAPITAL IV, L.P.

VERSANT SIDE FUND IV, L.P.

VERSANT VENTURES IV, LLC

  • 10% Owner
 5,174,727 2019-01-14 0

MOSBROOKER ERIC SVP, CHIEF COMMERCIAL OFFICER

  • Officer
 31,800 2019-01-03 2

NEWMAN MARY SVP, REGULATORY AFFAIRS

  • Officer
 660 2018-11-15 2

ORBIMED ADVISORS LLC

  • 10% Owner
 No longer subject to file 2018-10-09 0

WOIWODE THOMAS

  • Director
  • 10% Owner
 3,102,929 2018-10-02 0

GRAY JOHN T. SVP, CHIEF SCIENTIFIC OFFICER

  • Officer
 0 2018-09-28 1

NAGLER DAVID SVP, HR & CORP. AFFAIRS

  • Officer
 0 2018-06-20 1

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

ISALY SAMUEL D

  • 10% Owner
 1,868,966 2017-11-20 0

SQUINTO STEPHEN P

  • Director
 0 2017-10-08 0

5AM PARTNERS III, LLC

  • 10% Owner
 4,714,262 2016-07-25 0

VERSANT VENTURES IV, LLC

  • 10% Owner
 No longer subject to file 2016-07-25 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

PRASAD SUYASH - Officer SENIOR VP & CHIEF MED OFFICER

2019-05-13 S 54 $37.72 d 18,236 18,236.00 direct yes

PRASAD SUYASH - Officer SENIOR VP & CHIEF MED OFFICER

2019-05-13 S 9,946 $36.98 d 18,290 18,236.00 direct yes

PRASAD SUYASH - Officer SENIOR VP & CHIEF MED OFFICER

2019-05-13 M 10,000 d 30,870 18,236.00 direct yes

PRASAD SUYASH - Officer SENIOR VP & CHIEF MED OFFICER

2019-05-13 M 10,000 $0.79 a 28,236 18,236.00 direct yes

MELTZ MARK A - Officer SVP, GENERAL COUNSEL

2019-03-28 A 104,000 a 104,000 37,333.00 direct

MELTZ MARK A - Officer SVP, GENERAL COUNSEL

2019-03-28 A 37,333 a 37,333 37,333.00 direct

LANGE LOUIS G - Director

2019-03-25 S 19,700 $35.99 d 306,099 358,375.00 direct yes

LANGE LOUIS G - Director by amygdala lange trust

2019-03-25 S 1,000 $36.00 d 16,678 358,375.00 indirect yes

LANGE LOUIS G - Director

2019-03-25 S 300 $36.64 d 305,799 358,375.00 direct yes

LANGE LOUIS G - Director by lange minor's trust

2019-03-25 S 558 $35.94 d 0 358,375.00 indirect yes
Click here to report any possible errors with this stock listing.

Elevate your investments